Footnotes

Chapter 1 - Introduction

[1]        McKay B & Wells R, Commonwealth Review of Australian Blood and Blood Product System: Final Report, Department of Health and Human Services, Canberra, 1995.

[2]        Stephen, Sir N, Review of the Australian Blood Banking and Plasma Product Sector, Department of Health and Aged Care, Canberra, 2001.

[3]        Report of the Expert Advisory Group on Hepatitis C and Plasma in 1990, Department of Health and Ageing, Canberra, 2003.

[4]        Parliament of NSW, Legislative Council Standing Committee on Social Issues, Hepatitis C: The Forgotten Epidemic Inquiry into Hepatitis C in NSW, Report No 16, Parliament of NSW, Sydney, 1998.

[5]        Senate, Hansard, Question No. 1352, 15.5.03, p.11099; Question No. 1781, 18.9.03, p.15651, 26.1.03, p.18140; Question No. 2003, 24.11.03, pp.17616-17; Question No. 2004, 10.2.04, p.19742; Question No. 2005, 7.11.03, p.17463.

[6]        Information in this section is drawn largely from the Stephen Review and Barraclough Report.

[7]        Summarised in the Stephen Review, p.8.

[8]        Submission 64, p.16 (ARCBS).

[9]        Barraclough Report, p.24; Submission 54, Supplementary Submission, 21.5.04, p.4 (DoHA).

[10]      Submission 54, p.2 (DoHA). Note: the Commonwealth had responsibility for the ACT prior to self government in 1989.

[11]      Submission 64, p.16 (ARCBS).

[12]      Barraclough Report, p.24.

[13]      Submission 54, p.2 (DoHA).

[14]      Submission 54, p.2 (DoHA).

[15]      http://www.nba.gov.au. Accessed on 21 May 2004.

[16]      Stephen Review, p.xiv; Barraclough Report, p.5.

[17]      http://www.nba.gov.au. Accessed on 21 May 2004; National Blood Authority Act, s8.

[18]      http://www.nba.gov.au/pdf/national_blood_agreement.pdf. Accessed on 21 May 2004.

[19]      Submission 54, p.2 (DoHA).

[20]      See also Committee Hansard 5.4.04, p.43 (CSL).

Chapter 2 - Hepatitis C in Australia

[1]        Information used in this Chapter is drawn largely from the Report of the Expert Advisory Group on Hepatitis C and Plasma in 1990 (Barraclough Report), 2003 and the Review of the Australian Blood Banking and Plasma Product Sector (Stephen Review), 2001. Background information was also drawn from the Commission of Inquiry on the Blood System in Canada, (Krever Commission), 1997, Volume 2, Chapter 22.

[2]        The information in this timeline is based on the Krever Commission, Vol. 2; Submissions 54 (DoHA); 61 (AAPA); 64 (ARCBS).

[3]        http://www.hepatitisaustralia.com/pages/ABOUT_HEPATITIS.htm; Submission 64, p.20 (ARCBS).

[4]        Parliament of NSW, Legislative Council, Standing Committee on Social Issues, Hepatitis C: The Neglected Epidemic Inquiry into Hepatitis C in NSW, Report No 16, 1998, p.24.

[5]        Barraclough Report, pp.33-34.

[6]        Much of the data in this section was drawn from the National Centre in HIV Epidemiology and Clinical Research, HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report 2003, pp.11-13. Accessed at http://www.med.unsw.edu.au/nchecr/Downloads/03ansurvrpt.pdf on 12 May 2004.

[7]        Prevalence refers to total number of people in a population who have the disease at any given time.

[8]        Submission 64, p.27 (ARCBS).

[9]        Submission 54, p.16 (DoHA).

[10]      Submission 64, p. 68; Submission prepared for hearing 7.4.04, p.18 (ARCBS).

[11]      Submission 64, p. 68 (ARBCS).

[12]      Submissions 54, Appendix 3, p.A6 (DoHA); 64, p.21 (ARCBS). It should be noted that the Department of Health and Ageing commissioned Professor Cossart to address Terms of Reference (a), (b) and (f) due to their technical nature. These are at Appendices 2, 3 and 4 of the Department's submission.

[13]      Submission 64, p.22 (ARCBS); see also Submission 54, A9 (DoHA).

[14]      Barraclough Report, p.36.

[15]      Barraclough Report, p.36.

[16]      Submission 64, p.23 (ARCBS).

[17]      Submission 54, Appendix 3, p.A7 (DoHA).

[18]      Barraclough Report, p.37; Submission 64, p.37 (ARCBS).

[19]      Submission 64, p.23 (ARCBS).

[20]      Submissions 71, p.1 (ANZSBT); 82, p.8 (HFA).

[21]      Submission 82, p.8 (HFA).

[22]      Submission 64, p.24 (ARCBS).

[23]      Submission 64, p.25 (ARCBS).

[24]      Submission 71, p.1 (ANZSBT).

[25]      Barraclough Report, p.32.

[26]      Barraclough Report, pp.32-33.

[27]      Krever Commission, Volume 2, p. 628.

[28]      Submission 54, Appendix 3, p.A10 (DoHA).

[29]      See, for example, Committee Hansard 5.4.04 p.36 (Dr Baird); Submission 74, p.1-2 (Professor McCaughan); 86, p.3 (Prof W Cooksley).

[30]      Submission 69, p.1 (RCPA).

[31]      Submission 80, p.2 (ACHV).

[32]      See for example, Committee Hansard 5.4.04, p.26; Submission 79, p.2 (TBPAG).

[33]      Krever Commission, Volume 2, pp.630-32.

[34]      Submission 89, p.1 (Professor Mosley).

[35]      HJ Alter et al, 'Donor Transaminase and Recipient Hepatitis', Journal of American Medical Association, 246, no. 6, August 1981, pp.630-34.

[36]      Krever Commission, Volume 2, p.644.

[37]      Submission 64, pp.36-37 (ARCBS).

[38]      Hyland et al, 'Surrogate testing for non-A, non-B hepatitis in Queensland, Australia: An ALT Microtitre method for screening blood donors', Pathology, 1988, pp.271-74.

[39]      Submission 82, p.10; Committee Hansard 5.4.04, p.3 (HFA).

[40]      Submission 64, p.36 (ARCBS); see also Submission 69, p.1 (RCPA).

[41]      Submissions 64, p.36 (ARCBS); 86, p.2 (Prof W Cooksley).

[42]      Barraclough Report, p.39.

[43]      Submission 64, p.39 (ARCBS).

[44]      Submission 74, p.3-6 (Prof McCaughan).

[45]      Submission 54, p A15 (DoHA).

[46]      Committee Hansard 5.4.04, pp.47-48 (Dr Maher).

[47]      Submission 86, p.2 (Prof W Cooksley).

[48]      See, for example, Submission 74, p.1 (Prof McCaughan).

[49]      Barraclough Report, p. 40. See also Committee Hansard 6.4.04, p.62 (Prof Barraclough).

[50]      Submission 74, p.1 (Prof McCaughan).

[51]      Barraclough Report, p.41.

[52]      Submission 64, p.39; Submission prepared for hearing 7.4.04, p.12 (ARCBS).

[53]      Submission 64, p.42 (ARCBS).

[54]      Krever Commission, Volume 2, p.635.

[55]      See, for example, Submission 82, p.9 (HFA).

[56]      Barraclough Report, p.41.

[57]      Submission 64, Submission prepared for hearing 7.4.04, p.12 (ARCBS).

[58]      Submission 64, p.39; Submission prepared for hearing 7.4.04, p.12 (ARCBS).

[59]      Submission 64, Submission prepared for hearing 7.4.04, p.13 (ARCBS); see also Committee Hansard 5.4.04, p.51 (CSL).

[60]      Submission 64, Submission prepared for hearing 7.4.04, p.14 (ARCBS).

[61]      Submission 82, p.10 (HFA).

[62]      Submission 79, p.2. (TBPAG)

[63]      Submission 64, Response to Questions, 18.5.04, p.2 (ARCBS).

[64]      Submission 64, Response to Questions, 18.5.04, p.2 (ARCBS). The ARCBS emphasised that these figures were estimates only.

[65]      Submission 64, Submission prepared for hearing 7.4.04, p.13 (ARCBS).

[66]      Committee Hansard 6.4.04, p.65 (Professor Barraclough).

[67]      Submission 80, p.3 (ACHV).

[68]      Committee Hansard 5.4.04, p.36 (Dr Baird).

[69]      Submission 69, p.1 (RCPA).

[70]      Submission 64, pp.43-9 (ARCBS).

[71]      See also Committee Hansard 1.4.04, p.2 (ACHV).

[72]      Submission 54, Appendix 4, p.A22 (DoHA).

[73]      Barraclough Report, p.41.

[74]      Committee Hansard 1.4.04, p.4 (ACHV).

[75]      Committee Hansard 7.4.04, p.60 (ARCBS).

[76]      Barraclough Report, p.41.

[77]      Barraclough Report, p.42.

[78]      Committee Hansard 1.4.04, p.5 (ACHV).

[79]      Submission 64, Additional information, 10.5.04, p.1-4 (ARCBS).

[80]      For further information on the decisions taken regarding fractionated products at this time, see Barraclough Report, pp.60-82.

[81]      The description of events occurring around 1990 in this section was largely drawn from the Barraclough Report, pp. 5-16; 43-44.

[82]      Committee Hansard 6.4.04, p.37.

[83]      Barraclough Report, p.12.

[84]      Submission 64, supplementary submission 10.5.04, pp.2-3. (ARCBS).

[85]      Committee Hansard 1.4.04, p.4 (ACHV).

[86]      Committee Hansard 1.4.04, p.5 (ACHV).

[87]      Committee Hansard 5.4.04, p.29 (Professor Dax).

[88]      See, for example, Committee Hansard 6.4.04 p.65 (Professor Barraclough); Committee Hansard 5.4.04, p.46 (Dr Maher).

[89]      Committee Hansard 6.4.04, p.94 (Prof McCaughan).

[90]      Submission 81, Additional Information 9.6.04 p.4 (Hepatitis C Council of NSW)

[91]      Submission 54, p.12 (DoHA).

[92]      Submission 54, p.12 (DoHA).

[93]      Submission 64, p.62 (ARCBS).

[94]      Since 1990, various plasma products have been imported due to low demand. For a more detailed discussion, see Submission 64, p.64 (ARCBS).

[95]      Submission 64, p.62 (ARCBS). A state-by-state précis of the blood supply scenario in the 1980s is also available in the ARCBS Submission.

[96]      Submission 64, p.64 (ARCBS).

[97]      For detailed information on all blood products imported into Australia, see Senate, Hansard, Question No.1781, 18.9.03, pp.15652-3.

[98]      Stephen Review, p.xi.

[99]      Committee Hansard 5.4.04, p.7 (HFA).

[100]    Submission 74, p.19 (TBPAG).

[101]    Australian National Audit Office, Report on the Commonwealth Management and Regulation of Plasma Fractionation, ANAO, 1999.

[102]    Committee Hansard 5.4.04, p.45 (Dr Maher).

[103]    Submission 74, p.21 (TBPAG). See also Committee Hansard 6.4.04 p.39 (TBPAG).

[104]    Senate, Hansard, Question No. 1781, 18.9.03, p.15651. There are no records indicating that Queensland ever collected blood from prisons Submission 64, Supplementary Information 9.6.04 (ARCBS).

[105]    Submission 64, p.63 (ARCBS). The United States operates dual collection systems; one for fresh blood and one for plasma.

[106]    Submission 64, pp.44,47,63 (ARCBS).

[107]    Submission 64, p.63 (ARCBS).

[108]    Submission 64, pp.58-59 (ARCBS).

[109]    Submission 82, p.3 (HFA).

[110]    Submission 82, p.5 (HFA).

[111]    Submission 82, p.8 (HFA).

[112]    Confidential Submission 51, p.17.

[113]    Submission 64, pp.58-61 (ARCBS).

[114]    Committee Hansard 5.4.04, p.43 (CSL).

[115]    Committee Hansard 5.4.04, p.57 (CSL).

[116]    Committee Hansard 5.4.04, p.57 (CSL).

[117]    Submission 82, p.13 (HFA).

[118]    Committee Hansard 5.4.04, p.4 (HFA).

[119]    Confidential Submission 51, pp.28-29.

[120]    Submission 82, p.17 (HFA); Committee Hansard 5.4.04, p.53 (CSL).

Chapter 3 - The impact of Hepatitis C

[1]        Submission 8, p.5.

[2]        Parliament of NSW, Legislative Council, Standing Committee on Social Issues, Hepatitis C: The Neglected Epidemic Inquiry into Hepatitis C in NSW, Report No 16, 1998, p.23.

[3]        www.heptatitisaustralia.com

[4]        Committee Hansard 6.4.04, p.4 (Hepatitis C Council of NSW).

[5]        Committee Hansard 6.4.04, p.4 (Hepatitis C Council of NSW).

[6]        www.hepatitisaustralia.com

[7]        Submission 58, p.1.

[8]        Submission 51, p.1.

[9]        Confidential Submission 52, p.1.

[10]      Submission 54, p.23 (DoHA).

[11]      Committee Hansard 6.4.04, p.7 (Hepatitis C Council of NSW).

[12]      Submission 39, p.1.

[13]      Submission 82, p.22 (HFA).

[14]      Committee Hansard 5.4.04, p.21 (HFA).

[15]      Committee Hansard 6.4.04, p.8 (Hepatitis C Council of NSW).

[16]      Committee Hansard 5.4.04, p.6 (HFA).

[17]      Submission 82, p.22 (HFA).

[18]      Committee Hansard 5.4.04, p.7 (HFA).

[19]      Committee Hansard 6.4.04, p.49 (AHCDO).

[20]      Submission 70, p.25 (TBPAG); see also Committee Hansard 5.4.04, p.7 (HFA).

[21]      Committee Hansard 6.4.04, p.50 (AHCDO).

[22]      Submission 45, p.5.

[23]      Submission 82, p.24 (HFA).

[24]      Submission 65, p.5.

[25]      Committee Hansard 7.4.04, p.4.

[26]      Confidential Submission 53, p.2.

[27]      Committee Hansard 6.4.04, p.50 (AHCDO).

[28]      Confidential Submission 25, p.1.

[29]      Confidential Submission 38, p.1.

[30]      Submission 64, Submission prepared for hearing 7.4.04, p.39 (ARCBS).

[31]      Committee Hansard 6.4.04, p.10 (Hepatitis C Council of NSW).

[32]      Submission 19, p.1.

[33]      Submission 82, p.23 (HFA).

[34]      Submission 51 p.3.

[35]      Submission 70 p.1.

[36]      Committee Hansard 6.4.04, p.16 (Traids).

[37]      Committee Hansard 1.4.04, p.18 (AHC).

[38]      Submission 3, p.2.

[39]      Confidential Submission 33, p.2

[40]      Committee Hansard 5.4.04, p.7 (HFA).

[41]      Submission 47, p.1.

[42]      Submission 51, p.2.

[43]      Submission 10, p.1

[44]      Submission 65, p.5.

[45]      Confidential Submission 2, p.1.

[46]      Committee Hansard 7.4.04, p.8.

[47]      Submission 7, p.1.

[48]      Confidential Submission 1, p.5.

[49]      Confidential Submission 12, p.1.

[50]      Committee Hansard 6.4.04, p.15 (Traids).

[51]      Submission 7, p.1.

[52]      Submission 49, p.2.

[53]      Submission 4, p.1.

[54]      Submission 28, p.1.

[55]      Confidential Submission 10, p.1.

[56]      Submission 45, p.5.

[57]      Submission 40, p.2.

[58]      Parliament of NSW Legislative Council, Standing Committee on Social Issues, Hepatitis C: The Neglected Epidemic Inquiry into Hepatitis C in NSW, Report No 16, 1998; Anti-Discrimination Board of NSW, C Change: Report of the Enquiry into Hepatitis C Related Discrimination, 2001.

[59]      Submission 82, p.24 (HFA).

[60]      Submission 31, p.1.

[61]      Confidential Submission 17, p.1.

[62]      Submission 79, p.25 (TBPAG).

[63]      Committee Hansard 7.4.04, p.1.

[64]      Committee Hansard 1.4.04, p.17 (AHC).

[65]      Confidential Submission 18, p.2

[66]      Committee Hansard 6.4.04, p.16 (Traids).

[67]      Submission 7, p.2.

[68]      Submission 8, p.6.

[69]      Confidential Submission 14, p.1

[70]      Submission 15, p.2.

[71]      Submission 31, p.3; Committee Hansard 5.4.04, p.14 (HFA).

[72]      Confidential Submission 32, p.1.

[73]      Hepatitis C: The Neglected Epidemic, pp.108-117.

[74]      C Change: Report of the Enquiry into Hepatitis C Related Discrimination, Executive Summary.

The Krever Report

[1]        Krever H, Commission of Inquiry on the Blood System in Canada, 1997.

[2]        Much of Krever's discussion of the Canadian situation, particularly in relation to the evolution of opinion regarding surrogate testing, has been integrated into discussion in Chapter 2.

[3]        Krever Commission, Final Report, Volume 2, p.5.

[4]        Krever Commission, Final Report, Volume 2, p.990.

[5]        Submission 64 p.53 (ARCBS). The importance of incidence of Post-transfusion hepatitis in the Canadian context is discussed in Krever Commission, Final Report, Volume 2, pp.650-651.

[6]        See, for example, Committee Hansard 6.4.04 p.65 (Prof Barraclough).

[7]        Feineman et al, as contained in Submission 64, p. 53 (ARCBS).

[8]        Krever Commission, Final Report, Volume 2, p.993.

[9]        Committee Hansard 6.4.04 p.65 (Prof Barraclough).

[10]      Cossart YE et al, Post-transfusion hepatitis in Australia, Lancet 1982, 1:208-13.

[11]      Krever Commission, Final Report, Volume 2, p.706.

[12]      Krever Commission, Final Report, Volume 2, pp.985-1001.

[13]      See, for example, Committee Hansard 6.4.04 p.65 (Prof Barraclough); Committee Hansard 5.4.04 p.46 (Dr Maher).

[14]      Submission 64, p.50 (ARCBS).

[15]      Submission 64, p.50 (ARCBS).

[16]      Submission 54, p.10 (ARCBS).

Chapter 5 - Compensation arrangements

[1]        ACT Legislative Assembly, Hansard, 23.3.99, pp.685-88; 21.4.99, pp.1077-78.

[2]        In additional information provided to the Committee by the ACT Government, the cut off date for compensation eligibility was stated as 20 May 1991. Additional Information, 28.5.04, p.1.

[3]        ACT Legislative Assembly, Hansard, 23.3.99, pp.685-88.

[4]        ACT Legislative Assembly, Hansard, 21.4.99, pp.1077-78.

[5]        Submission 54, Supplementary Submission, 21.5.04, p.4 (DoHA).

[6]        Submission 54, Supplementary Submission, 21.5.04, p.5 (DoHA).

[7]        Submission 54, Supplementary Submission, 21.5.04, p.1 (DoHA).

[8]        Committee Hansard 1.4.04, p.27 (DoHA).

[9]        Committee Hansard 1.4.04, pp.27, 37 (DoHA).

[10]      Submission 54, Supplementary Submission, 21.5.04, p.4 (DoHA).

[11]      Queensland Government, Additional Information, 10.5.04, p.1.

[12]      New South Wales Government, Additional Information, 28.5.04, p.2.

[13]      Committee Hansard 6.4.04, pp.23, 32-33 (TBPAG).

[14]      Submission 8, p.3.

[15]      Committee Hansard 7.4.04, pp.39-40 (ARCBS).

[16]      Submission 54, p.10 (DoHA).

[17]      Committee Hansard 6.4.04, p.23 (TBPAG).

[18]      Submission 82, p.30; Committee Hansard 5.4.04, p.12 (HFA).

[19]      Submission 82, p.30 (HFA).

[20]      Submission 82, p.32 (HFA).

[21]      Submission 82, pp.31, 37-38 (HFA).

[22]      Submission 81, p.5 (Hepatitis C Council of NSW); see also Committee Hansard 1.4.04, p.13 (AHC).

[23]      Submission 82, Supplementary Submission, 31.5.04, p.4 (AHC); Committee Hansard 6.4.04, p.97 (Prof McCaughan).

[24]      Submission 82, p.31 (HFA).

[25]      The following information is based on Submissions 75, pp.19-24 (AHC); 82, pp.33-36 (HFA).

[26]      Submission 54, Additional Information, 26.5.04, pp.1-2 (DoHA).

[27]      Submission 79, p.26 (TBPAG).

[28]      Submission 21, p.1.

[29]      See for example, Submissions 7, p.2; 10, p.2.

[30]      Stephen, Sir N, Review of the Australian Blood Banking and Plasma Product Sector, Department of Health and Aged Care, Canberra, 2001, p.25.

[31]      Department of Health and Ageing, Annual Report 2001-02, p.165.

Chapter 6 - Services for people with Hapatitis C

[1]        Committee Hansard 7.4.04, p.6.

[2]        The modelling took into account survival rates of people receiving transfusions and estimated the possible number of Australians alive today with transfusion acquired hepatitis C. The upper limit was reduced by the number expected to have cleared the virus. The number of people with haemophilia who have hepatitis C was also included.

[3]        Submission 64, Submission prepared for hearing, 7.4.04, p.39; Committee Hansard 7.4.04, p.39 (ARCBS).

[4]        Committee Hansard 7.4.04, p.2.

[5]        Committee Hansard 6.4.04, p.31; Submission 79, Reference E, p.1 (TBPAG).

[6]        Committee Hansard 6.4.04, p.27 (TBPAG); Submissions 3, p.2; 33, p.2.

[7]        Committee Hansard 6.4.04, p.21 (TBPAG).

[8]        Committee Hansard 7.4.04, p.39 (ARCBS).

[9]        Committee Hansard 7.4.04, p.69 (ARCBS).

[10]      Submission 64, Submission prepared for hearing 7.4.04, p.17 (ARCBS).

[11]      Submission 64, p.88 (ARCBS).

[12]      Submission 64, Submission prepared for hearing, 7.4.04, p.17 (ARCBS).

[13]      Committee Hansard 7.4.04, p.70 (ARCBS).

[14]      Submission 64, p.88 (ARCBS).

[15]      NHMRC, Report on the Epidemiology, Natural History and Control of Hepatitis C, Nov 1993, pp.18-20.

[16]      Submission 64, Responses to questions, p.4 (ARCBS).

[17]      Submission 64, Submission prepared for hearing 7.4.04, p.21 (ARCBS).

[18]      Submission 64, Submission prepared for hearing 7.4.04, p.20 (ARCBS).

[19]      Submission 71, p.2 (ANZSBT).

[20]      Committee Hansard 7.4.04, pp.40,70 (ARCBS).

[21]      Stephen, Sir N, Review of the Australian Blood Banking and Plasma Product Sector, Department of Health and Aged Care, 2001, p.124.

[22]      Ministerial Inquiry conducted by Professor Richard Smallwood into the transmission of Human Immuno Deficiency Virus (HIV) to a recipient of a homologous blood donation at the Royal Children's Hospital, Melbourne in December 1998. Media release, Minster for Health, Mr J Thwaites, 9.12.99.

[23]      Stephen Review, pp.124-27.

[24]      Submission 54, Additional Information, 25.5.04 (DoHA).

[25]      Submission 54, pp.20-21 (DoHA).

[26]      Submission 54, Additional Information, 26.5.04, p.3 (DoHA).

[27]      Levy M, Baum F & Thomas H, Review of the National Hepatitis C Strategies: A Road Not Taken, July 2002.

[28]      Submission 54, p.21 (DoHA).

[29]      Submission 75, p.1 (AHC).

[30]      Committee Hansard 1.4.04, p.14; Submission 75, p.9 (AHC).

[31]      The PHOFAs are bilateral funding agreements between the Commonwealth and each State and Territory which provide broadbanded and special purpose funding from the Commonwealth to the States and Territories for a range of public health programs. These programs include the National Drug Strategy; National HIV/AIDS Strategy; National Immunisation Program and BreastScreen Australia.

[32]      Review of the National Hepatitis C Strategies, p.85.

[33]      Review of the National Hepatitis C Strategies, pp.86-92.

[34]      Review of the National Hepatitis C Strategies, p.92.

[35]      Submission 64, p.72 (ARCBS).

[36]      Submission 54, p.21 (DoHA).

[37]      Submission 54, p.21 (DoHA).

[38]      Submission 54, p.22 (DoHA).

[39]      Submission 54, p.23 (DoHA).

[40]      Submission 54, Additional Information, 26.5.04, p.3 (DoHA).

[41]      Submission 54, p.23; Additional Information, 1.6.04, p.2 (DoHA).

[42]      Submission 75, p.14 (AHC).

[43]      Submission 83, pp.1-2 (Traids).

[44]      www.taintedbloodnetwork.com

[45]      Submission 75, p.7 (AHC).

[46]      Committee Hansard 6.4.04, p.7 (Hepatitis C Council of NSW).

[47]      Submission 75, pp.7-8 (AHC).

[48]      Committee Hansard 1.4.04, p.21 (AHC).

[49]      Committee Hansard 6.4.04, p.13 (Traids); Committee Hansard 6.4.04, p.90 (Prof McCaughan).

[50]      Review of the National Hepatitis C Strategies p.116.

[51]      Submission 82, p.37 (HFA).

[52]      Submission 72, p.3 (AHDCO).

[53]      Submission 62, Submission prepared for hearing, 7.4.04, p.20 (ARCBS).

[54]      Submission 54, p.22 (DoHA).

[55]      Submission 54, p.22 (DoHA).

[56]      Submission 75, p.12 (AHC).

[57]      Submission 75, p.12 (AHC).

[58]      Personal communication with the Committee, Australian Society for HIV Medicine.

[59]      Committee Hansard 6.4.04, p.92 (Prof McCaughan).

[60]      Committee Hansard 6.4.04, p.10 (Hepatitis C Council of NSW).

[61]      Committee Hansard 5.4.05, p.16 (HFA).

[62]      Submission 75, p.5 (AHC).

[63]      Committee Hansard 1.4.04, p.15 (AHC).

[64]      Submission 8, pp.1-2.

[65]      Committee Hansard 6.4.04, p.12 (Traids).

[66]      Committee Hansard 6.4.05, p.10 (Hepatitis C Council of NSW).

[67]      Review of the National Hepatitis C Strategies, p.103.

[68]      Committee Hansard 6.4.04, p.14 (Traids).

[69]      Committee Hansard 1.4.04, p.15 (AHC).

[70]      Committee Hansard 1.4.04, p.32 (DoHA).

[71]      Committee Hansard 1.4.04, p.14 (Australian Hepatitis Council).

[72]      Committee Hansard 6.4.04, p.12 (Traids).

[73]      Committee Hansard 6.4.04, p.12 (Traids).

[74]      Committee Hansard 6.4.04, p.10 (Hepatitis C Council of NSW).

[75]      Submission 84, p.1 (Traids Support Group).

[76]      Committee Hansard 6.4.04, p.12.

[77]      Committee Hansard 5.4.04, p.21 (HFA).

[78]      Submission 84, p.3 (Traids Support Group).

[79]      Committee Hansard 6.4.04, p.15 (Traids).

[80]      Committee Hansard 5.4.05, pp.12-13 (HFA).

[81]      Committee Hansard 5.4.04, p.8 (HFA).

[82]      See for example, Submission 79, p.26 (TBPAG).

[83]      Submission 8, p.2.

[84]      Submission 72, p.2 (AHCDO).

[85]      Submission 82, p.15 (HFA); see also Committee Hansard 6.4.04, p.49 (AHCDO).

[86]      Committee Hansard 7.4.04, p.47 (ARCBS).

[87]      Submission 82, p.15 (HFA).

[88]      Australian Health Ministers' Advisory Council Blood and Blood Products Committee, Report on the Working Party on the Supply and use of Factor VIII and Factor IX in Australia, April 2003, p.6.

[89]      Submission 82, p.16 (HFA).

[90]      Committee Hansard 5.4.04, p.4 (HFA).

[91]      Submission 72, p.2 (AHCDO).

[92]      See for example, Committee Hansard 5.4.04, p.7 (HFA).

[93]      Committee Hansard 5.4.04, p.4 (HFA); Committee Hansard 7.4.04, p.47 (ARCBS).

[94]      Additional Information, Mr G Volk.

[95]      Committee Hansard 5.4.04, p.53 (CSL).

[96]      See for example, Committee Hansard 6.4.04, p.98 (Prof McCaughan).

[97]      Committee Hansard 6.4.04, p.17 (Traids).

[98]      Submission 75, p.14 (AHC).

[99]      Submission 75, p.8 (AHC). See also, Australian Government Response to the 2002 Review of the National HIV/AIDS and Hepatitis C Strategies and Strategic Research, p.15.

[100]    Submission 16, p.2.

[101]    Committee Hansard 5.4.04, p.11 (HFA).

[102]    Submission 8, p.6.

[103]    Committee Hansard 7.4.04, p.6.

[104]    Submission 64, Supplementary Submission, 27.5.04, pp.1-2 (ARCBS).

[105]    Submission 81, Supplementary Submission, 31.5.04, p.5 (Hepatitis C Council of NSW).

[106]    Submission 27, p.2.

Additional comments by Senator Steve Hutchins

[1] Committee Hansard, 6 April 2004, CA 44.

[2] Committee Hansard, 1 April 2004, CA 1.

[3] Australian Association of Pathology Practices, Submission 61, p. 3.

[4] Australian Red Cross Blood Service, Submission 64, p. 45.

[5] Australian Red Cross Blood Service, Submission 64, p. 37.

[6] Department of Health and Ageing, Submission 54, p.8.

[7] Australian Red Cross Blood Service, Submission 64, p. 94.

[8] Australian Red Cross Blood Service, Submission 64, p. 30.

[9] Committee Hansard, 7 April 2004, CA 38.

[10] Professor James W Mosley, Submission 89, p. 1.

[11] Ibid.